Facebook
Twitter
LinkedIn
Forward
Intravenous Iron in Inflammatory Bowel Disease: Closing Outcomes Chasms through the Effective Management of Iron Deficiency Anemia
A foundational review of IBD-associated IDA etiology and pathophysiology, as well as a detailed appraisal of the emerging clinical trial data catalyzing the evolving clinical utility of next-generation IV iron agents in IBD, will set the stage of an interactive data-driven discussion of how to safely and effectively implement these agents in practice. Using patient cases, clinical experts will evaluate the rationale for IV iron in IBD management, investigate currently-available agents, and provide practical solutions to real-world clinical questions from today’s gastroenterology clinic.
Target Audience
Gastroenterologists and members of their multidisciplinary, interprofessional inflammatory bowel disease (IBD) treatment team.
Learning Objectives
- Discuss the basic principles of iron metabolism and absorption, including the practical distinctions between functional and absolute iron deficiency, with a focus on how these principles apply to IDA treatment in IBD.
- Evaluate the role of iron deficiency as an etiology for anemia in IBD.
- Recognize the prevalence of comorbid IBD and IDA and describe the substantial impact of anemia on IBD patient-reported quality-of-life metrics and clinical outcomes.
- Review the essential utility of serum ferritin, transferrin saturation (TSAT), and C-reactive protein as diagnostic laboratory indices, alongside hemoglobin, for IDA in IBD.
- Examine the pathophysiologic principles of how inflammation and hepcidin affect iron availability and utilization, especially in an intrinsically hyperinflammatory condition like IBD, and the resultant rationale for preferential treatment with IV iron vs oral iron.
- Identify how next-generation IV iron products have improved upon the safety and efficacy profiles of older agents, with emphasis on dramatically reduced rates of severe hypersensitivity reactions, especially in the setting of IBD.
- Appraise completed, ongoing, and planned clinical trials of IV iron therapies for IDA management in IBD.
- Compare and contrast FDA-approved IV iron products, including new indications and dosing regimens.
- Identify how next-generation IV iron products have improved upon the safety and efficacy profiles of older agents, with emphasis on dramatically reduced rates of severe hypersensitivity reactions, especially in the setting of IBD.
- Design innovative, evidence-supported clinical tools that can interface with institutional EHRs, such as diagnostic algorithms, digitalized checklists to promote IBD GDMT, and Ganzoni’s formula to determine iron repletion dosages.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from American Regent.
Additional Information
| Attachment | Size |
|---|---|
 Handout and References | 2.83 MB |
| Clinical Took | 442.34 KB |
12:30-12:35 PM Welcome and Introductions/Pre-test
12:35-12:50 PM IDA in IBD: The Etiology, Epidemiology, and Pivotal Impact of Inflammation on Functional Iron Deficiency
12:50-1:05 PM What’s New and What’s Next: The Established Paradigm and the Evolving Evidentiary Base for Nextgeneration IV Iron Therapies in IBD
1:05-1:30 PM Gastroenterology Expert Exchange—Data-driven Discussions of Hyperinflammation, Hepcidin, and Real-world Implications for IV Iron in IBD Clinical Case Discussion, Post-test and Q&A
Neilanjan Nandi, MD, FACP (Activity Chair)
Associate Professor of Clinical Medicine
Penn Medicine
Philadelphia, PA
Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
Philadelphia, PA
Millie D. Long, MD, MPH
Professor of Medicine
Vice Chief, Division of Gastroenterology and Hepatology
School of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Planners/Faculty:
Gary R. Lichtenstein, MD–has disclosed that he has stock options in Virgo. He is an advisor or consultant to Abbvie, American Regent, Bristol Meyers Squibb, Celgene, Eli Lilly, Endo Pharmaceuticals, Ferring, Gilead, Janssen Orthobiotech, MedEd Consultants, Merck, Morphic Therapeutics, Pfizer, Prometheus Laboratories, Inc., Romark, Sandoz, Salix Pharmaceuticals / Valeant, Shire Pharmaceuticals, Takeda, and UCB. He also receives research support from Bristol Meyers Squibb, Celgene, Janssen Orthobiotech, and UCB.
Millie D. Long, MD, MPH–has disclosed that she is an advisor or consultant for AbbVie, Bristol Myers Squibb, Calibr, Janssen, Lilly, Pfizer, Prometheus, Salix, Takeda, Target PharmaSolutions, Theravance, and Valeant. She receives grant/research support from Pfizer and Takeda. Her institution receives grant/research support from AbbVie, Allergan, Amgen, Arena, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cosmos, Catalys, Pacific Covance, Genentech, Gossamer, OSK, Takeda and UCB Pharma. She is a member of the speakers bureaus for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda.
Neilanjan Nandi, MD, FACP–has disclosed that he is an advisor or consultant to Janssen and was an advisor or consultant to Boehringer Ingelheim, Bristol Myers Squibb, and Pfizer.
Peer Reviewer:
Information to come
CEC Staff/Planners:
Susan H. Gitzinger, PharmD, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.